Massachusetts Society of Clinical Oncologists - FDA approves selumetinib (Koselugo) for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas

"The voice for cancer physicians and their patients in Massachusetts."

Home
For Professionals
FDA Approvals
FDA approves selumetinib (Koselugo) for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas

FDA approves selumetinib (Koselugo) for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas

13 Apr 2020 8:31 AM | Anonymous

The U.S. Food and Drug Administration approved selumetinib (Koselugo; AstraZeneca) for neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurocfibromas (PN). Read full press release.

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org